ABSTRACT
Network medicine aims at unraveling cell signaling networks to propose personalized treatments for patients suffering from complex diseases. In this short review, we show the relevance of network medicine to cancer treatment by outlining the potential convergence points of the most recent technological and scientific developments in both drug design and signaling network analysis.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Design , Molecular Targeted Therapy , Neoplasms/drug therapy , Precision Medicine/methods , Animals , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Biomarkers/metabolism , Humans , Neoplasms/metabolism , Protein Interaction Maps , Protein Processing, Post-Translational , Signal Transduction , Systems BiologyABSTRACT
BACKGROUND AND PURPOSE: The CCR5 chemokine receptor is a member of the G protein-coupled receptor (GPCR) family that is expressed by macrophages, memory T-lymphocytes and dendritic cells and is activated by chemotactic proteins (e.g. MIP-1alpha [CCL3], MIP-1beta [CCL4] and RANTES [CCL5]). CCR5 is also the principal co-receptor for macrophage-tropic strains of human immunodeficiency virus-1 (HIV-1) and some chemokines can inhibit HIV-1 infection by stimulating CCR5 receptor endocytosis. The aim of this study was to evaluate the effect of CCR5 antagonists on CCR5 endocytosis. EXPERIMENTAL APPROACH: The effects of CCR5 agonists and antagonists on receptor internalization in CHO cells, expressing a C-terminal green fluorescent protein-tagged human CCR5 receptor (CCR5-GFP), were quantified using a confocal imaging plate reader. KEY RESULTS: MIP-1alpha [CCL3], MIP-1beta [CCL4] and RANTES [CCL5] were all able to stimulate potently the internalization of CCR5-GFP. This effect was inhibited by the non-peptide antagonist TAK 779. The CCR5 peptide antagonist met-RANTES antagonized MIP-1alpha-mediated increases in intracellular free calcium but was also able to stimulate a substantial internalization of the human CCR5-GFP receptor. However, CHO cells exhibited an aminopeptidase activity that was able to metabolize sufficient met-RANTES into an agonist metabolite capable of stimulating calcium mobilization via CCR5 receptors in naïve cells. CONCLUSIONS AND IMPLICATIONS: These data suggest that there is an endogenous aminopeptidase activity on the surface of CHO cells, that produces a slow internalization of the receptor following a time-dependent conversion of receptor-bound met-RANTES from a CCR5 receptor antagonist into a CCR5 agonist molecule.
Subject(s)
Aminopeptidases/drug effects , CCR5 Receptor Antagonists , Chemokine CCL5/pharmacology , Endocytosis/drug effects , Amides/pharmacology , Aminopeptidases/metabolism , Animals , CHO Cells , Calcium/metabolism , Chemokine CCL3/pharmacology , Chemokine CCL4/pharmacology , Chemokine CCL5/metabolism , Cricetinae , Cricetulus , Green Fluorescent Proteins , Humans , Luminescent Agents , Microscopy, Confocal , Quaternary Ammonium Compounds/pharmacology , Receptors, CCR5/agonists , Receptors, CCR5/metabolism , Time FactorsABSTRACT
Multi-element content and uranium (U) isotopes were investigated in the lichen Hypogymnia physodes (native and transplants) sampled across a 60-km transect, centred on Karabash smelter town, from Turgoyak Lake (SW) to Kyshtym (NE) to investigate the origin of U. Kyshtym was the site of a major nuclear accident in 1957. (234)U/(238)U activity ratios in native thalli sampled during July 2001 were within the natural isotopic ratio in minerals. Uranium/thorium (U/Th) ratios were higher in native thalli towards the NE (average 0.73) than those in the SW (average 0.57). Element signatures in native thalli and transplants suggest U was derived from fossil fuel combustion from Karabash and sources lying further to the east. Systematic and significant U enrichment indicative of a nuclear fuel cycle source was not detected in any sample. Element signatures in epiphytic lichen transplants and native thalli provide a powerful method to evaluate U deposition.
